Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis DOI Creative Commons
Ioannis Bellos, Smaragdi Marinaki,

Παγώνα Λάγιου

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 15(1), P. 39 - 39

Published: Dec. 31, 2024

Sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1a), and non-steroidal mineralocorticoid antagonists (ns-MRA) are promising treatments for chronic kidney disease. This umbrella review of network meta-analyses evaluated their effects on cardiovascular outcomes, disease progression, adverse events, using the TOPSIS method to identify optimal intervention based P-scores. A total 19 44 randomized controlled trials involving 86,150 patients were included. Compared placebo, SGLT2i associated with reduced risks events [Hazard ratio (HR): 0.776, 95% confidence intervals (CI): 0.727–0.998], progression (HR: 0.679, CI: 0.629–0.733), acute injury 0.873, 0.773–0.907), serious 0.881, 0.847–0.916). GLP1a ns-MRA also significant reductions in kidney-specific composite outcomes. Indirect evidence showed that demonstrated a lower risk compared 0.826, 0.716–0.952) 0.818, 0.673–0.995), representing best across all endpoints. In conclusion, while SGLT2i, GLP1a, reduce disease, appears provide most favorable balance efficacy safety.

Language: Английский

Empagliflozin ameliorates renal and metabolic derangements in obese type 2 diabetic mice by blocking advanced glycation end product–receptor axis DOI Creative Commons
Takanori Matsui, Ami Sotokawauchi,

Yuri Nishino

et al.

Molecular Medicine, Journal Year: 2025, Volume and Issue: 31(1)

Published: March 6, 2025

Language: Английский

Citations

1
Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis DOI Open Access
Takanori Matsui, Ami Sotokawauchi,

Yuri Nishino

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3007 - 3007

Published: March 26, 2025

Diabetes is associated with an increased risk of thromboembolism. However, the effects apixaban, a factor Xa inhibitor on diabetic nephropathy, remain unknown. Six-week-old Wistar rats received single 60 mg/kg intraperitoneal injection streptozotocin to produce model type 1 diabetes. Type and non-diabetic control were treated or without apixaban orally for 8 weeks, blood kidneys obtained biochemical, real-time reverse transcription-polymerase chain reaction (RT-PCR) morphological analyses. Although treatment did not affect glycemic lipid parameters, it significantly (p < 0.01) inhibited increases in advanced glycation end products (AGEs), receptor AGEs (RAGE) mRNA protein levels, 8-hydroxy-2'-deoxyguanosine (8-OHdG), NADPH oxidase-driven superoxide generation at 14 weeks old. Compared rats, gene expression levels monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule-1 (VCAM-1), transforming growth factor-β (TGF-β), connective tissue (CTGF), fibronectin 14-week-old which enhanced renal kidney injury (KIM-1) Mac-3, extracellular matrix accumulation kidneys, elevated urinary excretion KIM-1, all by apixaban. Urine KIM-1 positively correlated (r = 0.690) 8-OHdG 0.793) serum 0.823). Our present findings suggest that could ameliorate streptozotocin-induced partly blocking AGE-RAGE-oxidative stress axis kidneys.

Language: Английский

Citations

0
Comparative Efficacy and Safety of Cardio-Renoprotective Pharmacological Interventions in Chronic Kidney Disease: An Umbrella Review of Network Meta-Analyses and a Multicriteria Decision Analysis DOI Creative Commons
Ioannis Bellos, Smaragdi Marinaki,

Παγώνα Λάγιου

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 15(1), P. 39 - 39

Published: Dec. 31, 2024

Sodium-glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP1a), and non-steroidal mineralocorticoid antagonists (ns-MRA) are promising treatments for chronic kidney disease. This umbrella review of network meta-analyses evaluated their effects on cardiovascular outcomes, disease progression, adverse events, using the TOPSIS method to identify optimal intervention based P-scores. A total 19 44 randomized controlled trials involving 86,150 patients were included. Compared placebo, SGLT2i associated with reduced risks events [Hazard ratio (HR): 0.776, 95% confidence intervals (CI): 0.727–0.998], progression (HR: 0.679, CI: 0.629–0.733), acute injury 0.873, 0.773–0.907), serious 0.881, 0.847–0.916). GLP1a ns-MRA also significant reductions in kidney-specific composite outcomes. Indirect evidence showed that demonstrated a lower risk compared 0.826, 0.716–0.952) 0.818, 0.673–0.995), representing best across all endpoints. In conclusion, while SGLT2i, GLP1a, reduce disease, appears provide most favorable balance efficacy safety.

Language: Английский

Citations

0